X

Trial Profile

Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR)

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inotersen (Primary)
Indications Amyloid polyneuropathy
Focus Expanded access; Therapeutic Use
Sponsors Ionis Pharmaceuticals

Most Recent Events

26 May 2020 Results (N267), pooled analysis of 5 studies (NEURO-TTR, OLE, EAP, ATU, and IST) assessing outcomes of enhanced monitoring for thrombocytopenia in patients receiving inotersen presented at the 6th Congress of the European Academy of Neurology
08 Nov 2018 Status changed from recruiting to completed.
08 Jan 2018 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com